1 active not recruiting. 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Active not recruiting 1 |
Follow Dong Wen: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Vorolanib Monotherapy or in Combination With Toripalimab as Adjuvant Therapy for Patients With Intermediate-high Risk of Recurrence in Renal Cell Carcinoma Vorolanib Tablets, Vorolanib + Toripalimab - Renal Cell Carcinoma (RCC), Adjuvant | Phase 2 | Active not recruiting | Dong Wen | 60 | 2025-04-24 | 2025-07-09 |
toripalimab (1) · vorolanib (1)
China (1)